Avacta Group Plc (AVCT.L) Deep Dive Video

Name: Avacta Group Plc (AVCT.L) Deep Dive Video | Flash
Uploaded: 2026-03-23T00:19:46.956091
Description: AIM-listed Avacta is betting the company on clinically validating its FAP-activated pre|CISION “tumor-only” chemo platform—high upside if AVA6000/AVA6103 hit, high dilution and binary-data risk if they don’t.

Summary

AIM-listed Avacta is betting the company on clinically validating its FAP-activated pre|CISION “tumor-only” chemo platform—high upside if AVA6000/AVA6103 hit, high dilution and binary-data risk if they don’t.

View AVCT.L stock page · Read the AVCT.L research report

Loading the video player…